2-fluoro-6-(methylthio)pyridine

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-fluoro-6-(methylthio)pyridine
• 英文别名: 2-fluoro-6-methylsulfanylpyridine
• 化学式: C₆H₆FNS
• 分子量: 143.185
• InChiKey: WOOHSSSKQGPGOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-fluoro-6-(methylthio)pyridine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 16.5h， 以33.76%的产率得到3-bromo-2-fluoro-6-(methylthio)pyridine
  参考文献：
  名称：

  NOVEL GPR119 AGONIST COMPOUNDS

  摘要：

  本发明涉及公式（I）的新化合物，其制备方法以及包含这些化合物的组合物。

  公开号：

  US20170291894A1
• 作为产物：
  描述：

  2-氟吡啶 、 二甲基二硫 在 N,N-二甲基乙醇胺 、 trimethylsilylmethyllithium 作用下， 以 正己烷 、 四氢呋喃 为溶剂， 反应 3.0h， 以69%的产率得到2-fluoro-6-(methylthio)pyridine
  参考文献：
  名称：

  TMSCH2Li–LiDMAE: a new nonnucleophilic reagent for C-2 lithiation of halopyridines

  摘要：

  A new superbasic reagent has been discovered by combining TMSCHL(2)i and LiDMAE in hexane. This reagent was found highly efficient for the C-2 lithiation of sensitive chloro- and fluoropyridines. The metallation occurred chemo- and regioselectively at 0 degrees C avoiding the nucleophilic addition or substrate degradation commonly obtained with other alkyllithiums even at lower temperatures. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.04.059

文献信息

• GPR119 agonist compounds
  申请人：Mankind Pharma Ltd.

  公开号：US10208030B2

  公开（公告）日：2019-02-19

  The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

  本发明涉及新型式 (I) 化合物、其制备工艺以及包含这些化合物的组合物。
• γ-diketones as Wnt/β-catenin signaling pathway activators
  申请人：Samumed, LLC

  公开号：US10457672B2

  公开（公告）日：2019-10-29

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本公开提供了γ-二酮或其类似物，它们能激活Wnt/β-catenin信号转导，从而治疗或预防与信号转导有关的疾病，如骨质疏松症和骨关节病；成骨不全症、骨缺损、骨折、牙周病、耳硬化症、伤口愈合、颅面缺损、溶瘤性骨病、脑外伤或脊柱损伤、脑萎缩/与中枢神经系统分化和发育有关的神经系统疾病，包括帕金森病、中风、缺血性脑病、癫痫、阿尔茨海默病、抑郁症、躁狂症、精神分裂症；耳部疾病，如耳蜗毛细胞缺失；眼部疾病，如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性；以及与干细胞分化和生长有关的疾病，如脱发、造血相关疾病和组织再生相关疾病。
• HETEROCYCLIC GPR119 AGONIST COMPOUNDS
  申请人：MANKIND PHARMA LTD

  公开号：EP3440078A1

  公开（公告）日：2019-02-13
• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20190055227A1

  公开（公告）日：2019-02-21

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
• US4071521A
  申请人：——

  公开号：US4071521A

  公开（公告）日：1978-01-31